ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2297

Anti-TNF-α Exposure During Pregnancy: Impact on the Neonate’s Immune System

Yiyi Luo 1, Andrea Pluma 2, Raul Castellanos-Moreira3, Estefania Moreno 4, Nuria Baños 5, Sebastian DC Rodriguez-Garcia 6, Angela Deyà-Martínez 1, Ana Pilar Garcia-Garcia 1, Mireia Torres 7, Dolors Grados 8, Manel Casellas 9, Manel Juan 1, Ana Esteve-Sole 1 and Laia Alsina 10, 1Immunology Department. Center for Biomedical Diagnosis. Hospital Clínic of Barcelona IDIBAPS. Barcelona University. Barcelona. Functional unit of Clinical Immunology HSJD-HCP.Universidad de Barcelona. Pediatric Investigation Institute SJD, Barcelona, Spain, 2Hospital Universitari Vall d'Hebron, Barcelona, Spain, 3Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, 4Rheumatology Department. Vall d'Hebron University Hospital, Barcelona, Spain, Barcelona, Spain, 5Matern-Infantile Department, Hospital Clínic of Barcelona. Barcelona. Spain, Barcelona, Spain, 6Arthritis Unit. Rheumatology Department. Hospital Clinic of Barcelona. Barcelona. Spain, Barcelona, Spain, 7Neonatology Department. Vall d'Hebron University Hospital, Barcelona, Spain, Barcelona, Spain, 8Hospital d'Igualada, Barcelona, 9Hospital Universitari Vall d'Hebron, Barcelona, 10Hospital Sant Joan de Déu, Barcelona, Spain

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: anti-TNF therapy, immune system development and newborn, pregnancy

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Session Title: Reproductive Issues In Rheumatic Disorders Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Up to half of pregnant patients with rheumatic diseases experience disease activity which can increase the risk of pregnancy complications and poor disease outcomes. Treatment with anti-tumor necrosis factor-alpha (anti-TNF-α) is extendedly used in these patients to control disease activity. Placental drug barrier cross has been described for all anti-TNF-α, except for certolizumab. It occurs mainly during the third trimester of pregnancy. Few studies have evaluated the changes of newborn’s immune system upon this exposure. The aim of this study was to evaluate the impact of anti-TNF-α exposure during pregnancy on the newborn’s immune system, especially on lymphocyte subpopulations and innate immunity (IL-12 / IFN-γ pathway).

Methods: Prospective multicenter study which included newborns born to mothers with rheumatic diseases (including rheumatoid arthritis, spondyloarthropaties (ankylosing, psoriatic), juvenile idiopathic arthritis) , treated during pregnancy with anti-TNF-α.  A control group of newborns not exposed to anti-TNF-α during pregnancy was included.  All neonates underwent: a) clinical follow-up by a pediatric immunologist in search for infections, allergies or autoimmune disease; b) Umbilical cord (UC) and peripheral blood analysis at birth, 3, 6 and 12 months to record lymphocyte T and B subpopulations, analyze lymphocytes’ proliferation capacity, as well as vaccine responses and innate immunity against mycobacteria. All patients signed informed consent.

Results: Fourteen newborns have been included, 10 exposed to anti-TNF-α (Certolizumab: 6, throughout pregnancy; Etanercept: 4, of which 3 during throughout pregnancy) and 4 not exposed. Cohort features are summarized in table 1.

One child developed atopic dermatitis in the non-exposed group; no other allergies or autoimmune diseases have been reported. 7 infections (anti-TNF-α exposed: 3 vs non-exposed: 4) were diagnosed during follow-up. In 3 cases, the patient required hospitalization (1 pyelonephritis, 2 bronchiolitis). 

Conclusion: The preliminary results do not show an increase in the risk of infections or immune dysregulation in the anti-TNF-α exposed group.

No significant quantitative differences are observed in the lymphogenesis, but a more immature B population and a predominantly T memory population was found in newborns exposed to anti-TNF-α. These differences are attenuated at 3 and 6 months. Functional capacity of the IL-12 / IFN-γ pathway seems intact. The ongoing recruitment will give consistency to these results.


Table 1


Disclosure: Y. Luo, None; A. Pluma, None; R. Castellanos-Moreira, None; E. Moreno, None; N. Baños, None; S. Rodriguez-Garcia, None; A. Deyà-Martínez, None; A. Garcia-Garcia, None; M. Torres, None; D. Grados, None; M. Casellas, None; M. Juan, None; A. Esteve-Sole, None; L. Alsina, None.

To cite this abstract in AMA style:

Luo Y, Pluma A, Castellanos-Moreira R, Moreno E, Baños N, Rodriguez-Garcia S, Deyà-Martínez A, Garcia-Garcia A, Torres M, Grados D, Casellas M, Juan M, Esteve-Sole A, Alsina L. Anti-TNF-α Exposure During Pregnancy: Impact on the Neonate’s Immune System [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/anti-tnf-%ce%b1-exposure-during-pregnancy-impact-on-the-neonates-immune-system/. Accessed June 28, 2022.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-tnf-%ce%b1-exposure-during-pregnancy-impact-on-the-neonates-immune-system/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies